Pipeline_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Biocytogen is dedicated to the development of novel antibody drugs to meet the unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s pipeline includes more than 10 assets including monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and striving for clinical excellence, Biocytogen aims to deliver transformative therapies to patients in need.

Therapeutic Area

Product

Target(s)

Partner

Molecular Format

Indication(s)

Status

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Oncology

YH003

CD40

mAb

Solid tumors

YH001

CTLA-4

TRACON

mAb

Solid tumors

YH002

OX40

mAb

Solid tumors

YH004

4-1BB

mAb

Solid tumor + Hematological malignancy

YH005-ADC

Claudin18.2- ADC

Remegen

ADC

Solid tumors

YH008

PD-1 x CD40

Chipscreen NewWay

BsAb

Solid tumors

YH012

HER2 x TROP2

BsADC

Solid tumors

YH013

EGFR x MET

BsADC

Solid tumors

YH016

Undisclosed

Oncology

BCG003

TNFR2

Dragonboatbio

mAb

Solid tumors

BCG008

SIGLEC15

Undisclosed

mAb

Solid tumors

BCG011

TROP2 x EGFR

Undisclosed

BsADC

Oncology

BCG012

HER3 x MUC1

Undisclosed

BsADC

Oncology

BCG001

B7-H3

Mabworks

mAb

Solid tumors

BCG005

CCR8

LiberoThera

mAb

Solid tumors

BCG007

AMHR2

Undisclosed

mAb

Solid tumors

BCG002

CD24

mAb

Solid tumors

BCG006

WT1

Undisclosed

TCRm

Oncology

BCG010

NKG2A

Undisclosed

mAb

Oncology

BCG013

5T4 x MET

Undisclosed

BsADC

Oncology

Inflammation and Autoimmunity

YH015

CD40 inhibitor

mAb

Autoimmunity

YH017

Undisclosed

Autoimmunity

Infectious Diseases

BCG004

Rabies virus

Undisclosed

mAb

Infectious Diseases

Rare Diseases

BCG009

Undisclosed

mAb

Rare diseases

Oncology

YH003

Target：

CD40

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH001

Target：

CTLA-4

Partner：

TRACON

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH002

Target：

OX40

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH004

Target：

4-1BB

Partner：

Molecular Format：

mAb

Indication：

Solid tumor + Hematological malignancy

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH005-ADC

Target：

Claudin18.2- ADC

Partner：

Remegen

Molecular Format：

ADC

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH008

Target：

PD-1 x CD40

Partner：

Chipscreen NewWay

Molecular Format：

BsAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH012

Target：

HER2 x TROP2

Partner：

Molecular Format：

BsADC

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH013

Target：

EGFR x MET

Partner：

Molecular Format：

BsADC

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH016

Target：

Undisclosed

Partner：

Molecular Format：

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG003

Target：

TNFR2

Partner：

Dragonboatbio

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG008

Target：

SIGLEC15

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG011

Target：

TROP2 x EGFR

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG012

Target：

HER3 x MUC1

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG001

Target：

B7-H3

Partner：

Mabworks

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG005

Target：

CCR8

Partner：

LiberoThera

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG007

Target：

AMHR2

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG002

Target：

CD24

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG006

Target：

WT1

Partner：

Undisclosed

Molecular Format：

TCRm

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG010

Target：

NKG2A

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG013

Target：

5T4 x MET

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Inflammation and Autoimmunity

YH015

Target：

CD40 inhibitor

Partner：

Molecular Format：

mAb

Indication：

Autoimmunity

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH017

Target：

Undisclosed

Partner：

Molecular Format：

Indication：

Autoimmunity

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Infectious Diseases

BCG004

Target：

Rabies virus

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Infectious Diseases

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Rare Diseases

BCG009

Target：

Undisclosed

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Rare diseases

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Interested in partnering with us? Click to learn our collaboration models and contact us at BD-Licensing@biocytogen.com.

Collaboration Models